Close Menu

Biognosys

Working with ETH Zurich researchers, the firm has incorporated machine learning to improve the platform's performance in complex organisms like humans.

The company is working with German informatics firm MSAID to incorporate deep learning into mass spec analysis and with Biognosys on tools for quantitative work.

With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.

Biognosys will use its mass spectrometry technology to profile the proteome and phosphoproteome of clinical samples in Indivumed's oncology database.

While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.

The company announced the collaborations this week in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.

Roche ran a mock clinical trial in which it used DIA mass spec and targeted proteomics to profile 30 colorectal cancer samples under GCP conditions.

The group's meeting this week evidenced the ongoing shift towards analyzing proteins in the context of specific isoforms, complexes, and cells.

The recent agreement between Freenome and Biognosys suggests a role for proteomics as developers of genomic-based cancer detection tests look beyond ctDNA.

Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.